Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine-Reference-Cited by-同舟云学术

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine

Published:2019-02-20 Issue:4 Volume:15 Page:850-858
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Gouveia Miguel¹,Jesus Gonçalo²,Inês Mónica³,Costa João²⁴⁵,Borges Margarida²⁴⁶

Affiliation:

1. Católica Lisbon School of Business and Economics, Universidade Católica Portuguesa, Lisboa, Portugal

2. Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

3. Health Economics and Outcomes Research, Pfizer Portugal, Porto Salvo, Portugal

4. Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

5. Unidade de Farmacologia Clínica, Instituto de Medicina Molecular, Lisboa, Portugal

6. Unidade de Farmacologia Clínica, Centro Hospitalar Lisboa Central EPE, Lisbon, Portugal

Funder

Pfizer Biofarmacêutica, Sociedade Unipessoal Lda

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2018.1560769

Reference61 articles.

1. Clinical and economic burden of pneumococcal disease in older US adults

2. Implementing a Standardized Order Set for Community-Acquired Pneumonia: Impact on Mortality and Cost

3. Determinants of hospital costs in community-acquired pneumonia

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature;Human Vaccines & Immunotherapeutics;2023-11-28

2. Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review;Expert Review of Vaccines;2023-02-09

3. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan;Expert Review of Vaccines;2021-07-30

4. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China;Frontiers in Public Health;2021-05-24

5. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence;Expert Review of Vaccines;2021-02-20